These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 35308525)

  • 41. Microbiota-based treatments in alcoholic liver disease.
    Sung H; Kim SW; Hong M; Suk KT
    World J Gastroenterol; 2016 Aug; 22(29):6673-82. PubMed ID: 27547010
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Gut Barrier and Microbiota in Cirrhosis.
    Philips CA; Augustine P
    J Clin Exp Hepatol; 2022; 12(2):625-638. PubMed ID: 35535069
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dietary
    Zhao M; Chen C; Yuan Z; Li W; Zhang M; Cui N; Duan Y; Zhang X; Zhang P
    Exp Ther Med; 2021 Nov; 22(5):1312. PubMed ID: 34630666
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ellagic Acid Prevents Binge Alcohol-Induced Leaky Gut and Liver Injury through Inhibiting Gut Dysbiosis and Oxidative Stress.
    Kim DH; Sim Y; Hwang JH; Kwun IS; Lim JH; Kim J; Kim JI; Baek MC; Akbar M; Seo W; Kim DK; Song BJ; Cho YE
    Antioxidants (Basel); 2021 Aug; 10(9):. PubMed ID: 34573017
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Gut Microbiome and Alcohol-associated Liver Disease.
    Philips CA; Schnabl B; Bajaj JS
    J Clin Exp Hepatol; 2022; 12(5):1349-1359. PubMed ID: 36157139
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Gut microbiota, cirrhosis, and alcohol regulate bile acid metabolism in the gut.
    Ridlon JM; Kang DJ; Hylemon PB; Bajaj JS
    Dig Dis; 2015; 33(3):338-45. PubMed ID: 26045267
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Beneficial Effects of Natural Extracts and Bioactive Compounds on the Gut-Liver Axis: A Promising Intervention for Alcoholic Liver Disease.
    Zhao L; Wang S; Zhang N; Zhou J; Mehmood A; Raka RN; Zhou F; Zhao L
    Antioxidants (Basel); 2022 Jun; 11(6):. PubMed ID: 35740108
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Alcoholic liver disease: the gut microbiome and liver cross talk.
    Hartmann P; Seebauer CT; Schnabl B
    Alcohol Clin Exp Res; 2015 May; 39(5):763-75. PubMed ID: 25872593
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Gut Microbiota: Target for Modulation of Gut-Liver-Adipose Tissue Axis in Ethanol-Induced Liver Disease.
    Patel D; Sharma D; Mandal P
    Mediators Inflamm; 2022; 2022():4230599. PubMed ID: 35633655
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Exosome-Like Nanoparticles From
    Gu Z; Li F; Liu Y; Jiang M; Zhang L; He L; Wilkey DW; Merchant M; Zhang X; Deng ZB; Chen SY; Barve S; McClain CJ; Feng W
    Hepatol Commun; 2021 May; 5(5):846-864. PubMed ID: 34027273
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The gut microbiota: A new target in the management of alcohol dependence?
    Leclercq S; Stärkel P; Delzenne NM; de Timary P
    Alcohol; 2019 Feb; 74():105-111. PubMed ID: 30031625
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Alcoholic liver disease: focus on prodromal gut health.
    Park B; Lee HR; Lee YJ
    J Dig Dis; 2016 Aug; 17(8):493-500. PubMed ID: 27356233
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dysbiosis-induced intestinal inflammation activates tumor necrosis factor receptor I and mediates alcoholic liver disease in mice.
    Chen P; Stärkel P; Turner JR; Ho SB; Schnabl B
    Hepatology; 2015 Mar; 61(3):883-94. PubMed ID: 25251280
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dimethyl fumarate ameliorates hepatic inflammation in alcohol related liver disease.
    Sangineto M; Grabherr F; Adolph TE; Grander C; Reider S; Jaschke N; Mayr L; Schwärzler J; Dallio M; Moschen AR; Moschetta A; Sabbà C; Tilg H
    Liver Int; 2020 Jul; 40(7):1610-1619. PubMed ID: 32306456
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Connecting the immune system, systemic chronic inflammation and the gut microbiome: The role of sex.
    Rizzetto L; Fava F; Tuohy KM; Selmi C
    J Autoimmun; 2018 Aug; 92():12-34. PubMed ID: 29861127
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Alcohol, Inflammation, and Microbiota in Alcoholic Liver Disease.
    Dukić M; Radonjić T; Jovanović I; Zdravković M; Todorović Z; Kraišnik N; Aranđelović B; Mandić O; Popadić V; Nikolić N; Klašnja S; Manojlović A; Divac A; Gačić J; Brajković M; Oprić S; Popović M; Branković M
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835145
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Targeting the gut microbiota to treat alcoholic liver diseases: evidence and promises.
    Leclercq S; de Timary P; Stärkel P
    Acta Gastroenterol Belg; 2020; 83(4):616-621. PubMed ID: 33321019
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Modulating phenylalanine metabolism by L. acidophilus alleviates alcohol-related liver disease through enhancing intestinal barrier function.
    Chen L; Yang P; Hu L; Yang L; Chu H; Hou X
    Cell Biosci; 2023 Feb; 13(1):24. PubMed ID: 36739426
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development.
    Mouries J; Brescia P; Silvestri A; Spadoni I; Sorribas M; Wiest R; Mileti E; Galbiati M; Invernizzi P; Adorini L; Penna G; Rescigno M
    J Hepatol; 2019 Dec; 71(6):1216-1228. PubMed ID: 31419514
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease.
    Paolella G; Mandato C; Pierri L; Poeta M; Di Stasi M; Vajro P
    World J Gastroenterol; 2014 Nov; 20(42):15518-31. PubMed ID: 25400436
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.